1. Home
  2. BCDA vs POAI Comparison

BCDA vs POAI Comparison

Compare BCDA & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • POAI
  • Stock Information
  • Founded
  • BCDA N/A
  • POAI 2002
  • Country
  • BCDA United States
  • POAI United States
  • Employees
  • BCDA N/A
  • POAI N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • POAI Industrial Specialties
  • Sector
  • BCDA Health Care
  • POAI Health Care
  • Exchange
  • BCDA Nasdaq
  • POAI Nasdaq
  • Market Cap
  • BCDA 7.9M
  • POAI 9.7M
  • IPO Year
  • BCDA N/A
  • POAI N/A
  • Fundamental
  • Price
  • BCDA $2.72
  • POAI $1.48
  • Analyst Decision
  • BCDA Strong Buy
  • POAI Hold
  • Analyst Count
  • BCDA 1
  • POAI 1
  • Target Price
  • BCDA $25.00
  • POAI N/A
  • AVG Volume (30 Days)
  • BCDA 53.2K
  • POAI 2.8M
  • Earning Date
  • BCDA 03-26-2025
  • POAI 03-27-2025
  • Dividend Yield
  • BCDA N/A
  • POAI N/A
  • EPS Growth
  • BCDA N/A
  • POAI N/A
  • EPS
  • BCDA N/A
  • POAI N/A
  • Revenue
  • BCDA $71,000.00
  • POAI $1,484,223.00
  • Revenue This Year
  • BCDA N/A
  • POAI N/A
  • Revenue Next Year
  • BCDA N/A
  • POAI $569.48
  • P/E Ratio
  • BCDA N/A
  • POAI N/A
  • Revenue Growth
  • BCDA N/A
  • POAI N/A
  • 52 Week Low
  • BCDA $1.63
  • POAI $0.55
  • 52 Week High
  • BCDA $8.85
  • POAI $3.76
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 64.47
  • POAI 56.75
  • Support Level
  • BCDA $2.27
  • POAI $1.37
  • Resistance Level
  • BCDA $2.78
  • POAI $1.58
  • Average True Range (ATR)
  • BCDA 0.28
  • POAI 0.12
  • MACD
  • BCDA 0.03
  • POAI -0.02
  • Stochastic Oscillator
  • BCDA 91.04
  • POAI 48.39

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About POAI Predictive Oncology Inc.

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Share on Social Networks: